HONG KONG, June 1, 2011 /CNW/ - AlphaRx Inc. (OTC BB:ALRX.OB) announced
today that the Board of Directors of the Company has terminated Dr.
Joseph Schwarz and Dr. Michael Weisspapir, the Chief Scientist and the
Chief Medical Officer of the Company respectively, for violations of
the Company's policies and procedures. The Company has reserved any and
all legal recourse against Drs. Schwarz and Weisspapir.
The Company also announced that it will promptly begin a search for a
new Chief Scientist.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary drug
delivery systems to develop novel formulations of drugs that are
insoluble or poorly soluble in water or have yet to be administrable to
the human body with an acceptable delivery method. The Company's
product candidates address various pharmaceutical markets, including
pain and stroke.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and
pursuant to the Safe Harbor provisions of the Securities Litigation
Reform Act of 1995 and involve risks and uncertainties that may
individually or mutually impact the matters herein described, including
but not limited to product development and acceptance, manufacturing,
competition, regulatory and/or other factors, which are outside the
control of the Company.
This press release is available on the company's official on-line
investor relations site for investor commentary, feedback and
SOURCE AlphaRx Inc.
For further information: